Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

To determine the long-term effects of ranibizumab (RBZ) in patients with diabetic macular edema (DME). Prospective, randomized, interventional, multicenter clinical trial. One hundred twenty-six patients with DME. Subjects were randomized 1:1:1 to receive 0.5 mg RBZ at baseline and months 1, 3, and...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Ophthalmology (Rochester, Minn.) Ročník 117; číslo 11; s. 2146
Hlavní autoři:	Nguyen, Quan Dong, Shah, Syed Mahmood, Khwaja, Afsheen A, Channa, Roomasa, Hatef, Elham, Do, Diana V, Boyer, David, Heier, Jeffery S, Abraham, Prema, Thach, Allen B, Lit, Eugene S, Foster, Bradley S, Kruger, Erik, Dugel, Pravin, Chang, Thomas, Das, Arup, Ciulla, Thomas A, Pollack, John S, Lim, Jennifer I, Eliott, Dean, Eliot, Dean, Campochiaro, Peter A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.11.2010
Témata:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Combined Modality Therapy Diabetic Retinopathy - drug therapy Fluorescein Angiography Humans Injections Laser Coagulation Macular Edema - drug therapy Prospective Studies Ranibizumab Retreatment Time Factors Tomography, Optical Coherence Treatment Outcome Visual Acuity - physiology Vitreous Body
ISSN:	1549-4713, 1549-4713
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!